Does synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma require p53 activity?
The synergy of IFN-alpha and 5-FU requires p53 activity, suggesting that p53 status may serve as a predictive factor for response to the combination therapy. Because metastatic RCC frequently has p53 mutations, therapy restoring p53 may markedly improve the response rate of immunochemical therapy combining IFN-alpha and 5-FU.
Influenzinum RC altered cellular and biochemical features of MDCK and J774G8 cells.